JBS SCIENCE
Company Snapshot
Company Overview
JBS Science Inc. is developing and commercializing urine-derived cfDNA-based liquid biopsy diagnostics for cancer screening and management.
In September 2018, JBS Science was awarded a $3 million Phase IIB Bridge award from the National Cancer Institute to help commercialize its liquid biopsy test for the early detection of hepatocellular carcinoma (HCC). This funding will be used to run a blinded validation study together with two clinical partners: Daryl Lau (Harvard University) and Terence Gade (University of Pennsylvania).
The HCC assay isolates cancer-derived DNA in the urine and then uses unique PCF assays to identify ctDNA biomarkers related to this cancer.
JBS is partnered with Richen-Forge Holding (China), whose subsidiary, Richen-Forge Science & Technology, will commercialize the HCC test in China and other areas within Asia.
In addition to the HCC test, JBS is developing several other liquid biopsy assays, using funding from the NCI and NIH, for liver and colon cancers.
Company's Business Segments
- Liquid Biopsy : JBS Translates circulating cell-free DNA (cfDNA) in Urine Technology into improved Cancer Screening and Management by Liquid Biopsy towards decreased Global Cancer Mortality.
Applications/End User Industries
- Cancer
- PCR Kits
- Cancer Screening
- Clinics
- Healthcare
- Hospitals
- JBS Technology
- Acid Purification
- Liquid Biospy
- Urine Testing Kits
- Biotechnology Research
- Cancer Research
- Liquid Biopsy
- CfDNA
- Urine Technology
- Medical Research
